In this article for the "Highlights of 2024" series, we discuss antibody-drug conjugates (ADCs), which are an emerging class of targeted cancer therapies that harness the specificity of monoclonal antibodies to deliver cytotoxic agents directly to tumor cells. ADCs bind to tumor-associated antigens, undergo internalization via receptor-mediated endocytosis, and release their cytotoxic payload intracellularly, reducing systemic toxicity. This highly selective mechanism has led to significant advancements in oncology, improving treatment efficacy while minimizing adverse effects.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/imcb.70017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advances in Therapy of Adult Patients with Acute Lymphoblastic Leukemia.
Cells
March 2025
Department of Hematology and Medical Oncology, Advocate Lutheran General Hospital, Park Ridge, IL 60068, USA.
The landscape of adult acute lymphoblastic leukemia (ALL) is dramatically changing. With very promising results seen with novel immunotherapeutics in the setting of relapsed and refractory disease, the prospect of using these agents in first-line therapy has prompted the development of multiple clinical trials addressing this question. This review seeks to outline and expand the current standard of care, as well as new advances, in the treatment of adult patients with ALL and address future areas of research.
View Article and Find Full Text PDFDevelopment of Antibody-Drug Conjugates for Malignancies of the Uterine Corpus: A Review.
Cells
February 2025
Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo 104-0045, Japan.
Despite recent advances in cancer treatment, the prognosis for uterine malignancies (carcinoma and sarcoma) requires further improvement. Antibody-drug conjugates (ADCs) have emerged as a novel class of anti-cancer therapeutic agents, and multiple ADCs have been approved for other types of cancer. In 2024, trastuzumab deruxtecan received approval from the US Food and Drug Administration for cancer types and became the first ADC approved for the treatment of uterine malignancies.
View Article and Find Full Text PDFTherapeutic perspectives for recurrent or metastatic head and neck squamous cell carcinoma.
Curr Opin Oncol
March 2025
Centre Léon Bérard, Lyon, France.
Purpose Of Review: Recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) remains a significant therapeutic challenge due to its biological complexity and clinical heterogeneity. This review addresses the relevance of exploring novel therapeutic approaches, particularly in light of recent advances and the persistent unmet needs in patient outcomes.
Recent Findings: Recent phase II and III clinical trials have highlighted promising strategies, including combinations of immunotherapy with targeted therapies, antibody-drug conjugates (ADCs), HPV vaccines, dual immunotherapy approaches, and therapies targeting the tumor microenvironment.
A review of antibody-based immunotherapy clinical trials for adult acute myeloid leukemia (AML): monoclonal antibodies (mAbs) and beyond.
Expert Opin Biol Ther
March 2025
Division of Blood and Marrow Transplantation, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Introduction: Antibody-based immunotherapies are a class of therapeutics under active investigation in clinical trials for the treatment of acute myeloid leukemia (AML). Our review provides a comprehensive examination of trials published to date, focusing on recurrent challenges and promising aspects of antibody-based therapeutics.
Areas Covered: We described antibody-based immunotherapies for AML, specifically, an overview of the most prominent antigen targets in published clinical trials investigating monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, and chimeric antigen receptor therapies.
Antibody-DNA nanostructure conjugate enables targeted delivery of gemcitabine to tumor and improves the anti-tumor efficacy.
J Control Release
March 2025
Institutes of Biomedical Sciences, School of Stomatology & Shanghai Stomatological Hospital, Fudan University, Shanghai 200032, China. Electronic address:
Antibody drug conjugate has emerged as one of the most successful drug delivery systems in recent years. Leveraging the inherent self-assembly and efficient intracellular internalization capabilities of DNA nanostructures, this study aimed to develop antibody-DNA nanostructure conjugates based on gemcitabine, which drug antibody ratio can reach 17.8.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!